{"filings":[{"id":2357639,"accession_number":"0001104659-26-098830","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-08-19T21:24:24+00:00","items":["8.01","9.01"],"status":"ready","headline":"Twist Bioscience files prospectus supplement to register resale of shares to Invenra","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Registers resale of shares issuable under Feb 11, 2026 Stock Purchase Agreement with Invenra Inc.","Prospectus supplement filed; Orrick opinion on validity attached as Exhibit 5.1.","No share count, value, or terms disclosed in this filing.","Procedural registration of existing resale rights; no new business activity reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2336523,"accession_number":"0001581280-26-000050","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-08-18T22:15:54+00:00","items":["7.01"],"status":"ready","headline":"Anthropic selects Twist Bioscience as evaluator for AI-designed protein campaign across 15 targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anthropic chose Twist as independent evaluator for multi-arm protein design campaign against 15 targets.","Campaign uses Claude Opus 4.8 and Mythos Preview to design proteins; Twist will produce and test binding.","Twist to rapidly produce AI-designed proteins at scale and test designs for binding.","Announcement made via Anthropic blog post on August 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2081476,"accession_number":"0001104659-26-091280","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-08-05T21:27:14+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Twist Bioscience prices upsized $300M public offering of common stock at $96/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,125,000 shares at $96.00 per share; underwriters' option for 468,750 additional shares exercised in full.","Net proceeds expected to be approximately $327.1 million after underwriting discounts and expenses.","Offering upsized from originally proposed $250 million to $300 million; expected to close August 6, 2026.","Proceeds to fund R&D, manufacturing capacity expansion, product offerings, and working capital.","Joint book-running managers: Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2006396,"accession_number":"0001581280-26-000044","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-08-03T11:21:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q3 FY2026 revenue $118.4M (+23% YoY); raises FY guidance to $456-457M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue of $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth.","Gross margin 52.8%, up 120 bps sequentially; DSPS revenue $56.6M (+39% YoY), NGS $61.8M (+12% YoY).","Net loss $35.1M ($0.56/share) vs net income $20.4M ($0.33) in prior year which included $48.8M gain from Atlas spin-out.","Adjusted EBITDA -$11.3M; company reiterates Q4 FY2026 adjusted EBITDA breakeven target.","FY2026 revenue guidance raised to $456-457M, up $12M at midpoint; cash $167M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93839,"accession_number":"0001581280-26-000037","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).","DSPS revenue $53.3M (+28% YoY); NGS revenue $57.4M (+12% YoY).","Net loss $44M ($0.71/share) vs $39.3M ($0.66/share) YoY; adjusted EBITDA loss improved to $13.3M from $14.8M.","Raised FY2026 revenue guidance to $442-447M; reiterates Q4 FY26 adjusted EBITDA breakeven.","Booked $7.2M litigation settlement cost for securities class action; entered bispecific licensing with Invenra."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":214413000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105772,"accession_number":"0001104659-26-015730","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Twist Bioscience to issue up to 632,328 shares for Invenra license and equity stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: up to 632,328 TWST shares plus $5M cash.","324,558 shares + $5M to Invenra for license and technology transfer.","307,770 shares to two Invenra investors for ~6% preferred stock ownership.","Twist gains right to designate one director to Invenra board.","Registration Rights Agreements filed to register resale of issued shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105771,"accession_number":"0001581280-26-000022","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Twist Bioscience stockholders elect three directors, approve say-on-pay and auditor ratification at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Keith Crandell, Jan Johannessen, and Trynka Shineman Blake elected as Class II directors with over 40M votes for each.","Non-binding advisory vote to approve NEO compensation passed: 38.4M for, 11.8M against, 32.7K abstentions.","Ratification of Ernst & Young as auditor for FY2026 approved: 56.2M for, 18.2K against, 21.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105770,"accession_number":"0001581280-26-000016","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.","Gross margin 52.0% (+4 pts YoY); net loss narrowed to $30.5M ($0.50/share) vs $31.6M.","DNA Synthesis & Protein Solutions rev $51.1M (+27% YoY); NGS Apps $52.6M (+8%, ex-large customer +18%).","FY2026 revenue guidance raised to $435-440M; reaffirms Q4 Adj EBITDA breakeven on track.","Cash $198M; shipped to ~2,538 customers, ~271,000 genes; launched research-grade plasmid DNA preps."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":103698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105769,"accession_number":"0001581280-26-000012","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.","DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.","NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.","Full Q1 financial results to be reported on Feb 2, 2026, before market open."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":103698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122057,"accession_number":"0001581280-25-000020","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.","FY25 gross margin 50.7% vs 42.6% in FY24; Q4 gross margin 51.3% vs 45.1%.","NGS segment revenue grew 23% to $208.1M; SynBio grew 17% to $145.0M; Biopharma grew 15% to $23.5M.","Net loss narrowed to $77.7M ($1.30/share) from $208.7M ($3.60/share); adjusted EBITDA -$46.9M vs -$93.5M.","FY2026 guidance: maintain gross margin >50%; target adjusted EBITDA breakeven by Q4 FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":376572000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138768,"accession_number":"0001581280-25-000012","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Twist Bioscience appoints Trynka Shineman Blake to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trynka Shineman Blake elected to Twist board and appointed to Audit Committee, effective August 5, 2025.","Blake most recently served as CEO of Vistaprint; brings ~30 years in digital transformation, customer experience, and global marketing.","Compensation includes $50k annual cash retainer, $10k audit retainer, initial RSU of $395k fair value, and annual RSU of $240k.","Blake also serves on boards of Tripadvisor, Semrush, Captura, and Steer.","CEO Emily Leproust cites Blake's proven track record in scaling profitable growth and customer-centric culture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138767,"accession_number":"0001581280-25-000006","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.","Gross margin improved to 53.4% from 43.3% YoY; net income $20.4M ($0.34/share) vs loss $85.6M.","FY2025 revenue guidance raised to $374-376M; gross margin guidance raised to 50.5%-51%.","Adjusted EBITDA loss narrowed to $(8.0)M from $(22.0)M; expect breakeven by end of FY2026.","Added ~184 net new customers; shipped 237,000 genes, up 12% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":277563000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156218,"accession_number":"0001104659-25-044352","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Twist reports record Q2 revenue $92.8M; spins out DNA data storage as Atlas with $155M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record Q2 revenue $92.8M (+23% YoY); gross margin 49.6% vs 41.0%.","Net loss $39.3M ($0.66/sh) vs $45.5M ($0.79); adjusted EBITDA loss improved to $(14.8)M.","Spun out DNA data storage as Atlas Data Storage with $155M investment from ARCH, Deerfield, Bezos Expeditions, and others.","Atlas CEO Varun Mehta (ex-Nimble Storage) leads; Twist retains minority stake, $2.5M cash, $2M note, up to $75M milestones.","Guidance: FY2025 revenue $372-379M; expect gross margin >50% in Q4; adjusted EBITDA breakeven by end of FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174672,"accession_number":"0001104659-25-011543","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Twist Bioscience shareholders approve 100M share increase, equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common stock by 100,000,000 shares (Proposal Five).","Amendment and restatement of 2018 Equity Incentive Plan approved; 3,700,000 new shares reserved (Proposal Four).","Directors Nelson Chan, Robert Ragusa, Melissa Starovasnik re-elected as Class I directors.","Non-binding advisory vote on NEO compensation passed with 49.6M votes for; 1.2M against.","Officer exculpation amendment approved (46.5M for, 4.3M against) effective upon filing Certificate of Amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174671,"accession_number":"0001628280-25-003387","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.","Gross margin improved 7.8 points to 48.3% from 40.5% in prior year period.","Net loss per share ($0.53) vs ($0.75) YoY; adjusted EBITDA ($16.3M) vs ($27.8M).","FY2025 revenue guidance $372M-$379M; expects gross margin over 50% in Q4 FY2025.","Cash and short-term investments $270.8M at Dec 31, 2024; shipped to ~2,376 customers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":88713000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191639,"accession_number":"0001628280-24-048173","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.","Gross margin improved to 45.1% in Q4FY24 (from 36.6%); net loss narrowed to $34.7M ($0.59/share) from $46.2M ($0.81/share).","FY2025 guidance: revenue $367M-$377M; targeting 50% gross margin by Q4FY25.","Adjusted EBITDA improved to -$93.5M FY2024 vs -$147.3M FY2023; cash $276.4M at year-end.","Entered $15M royalty purchase agreement with XOMA; launched FlexPrep NGS kit with proprietary enzyme."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":312974000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191638,"accession_number":"0001104659-24-108591","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Twist Bioscience enters month-to-month consulting agreement with James Thorburn at $25K/mo","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Thorburn's previous employment agreement as Strategic Advisor expired; new consulting deal effective October 8, 2024.","Consulting agreement is month-to-month at $25,000 per month to complete certain projects.","No departure of director or officer; Thorburn continues in a limited advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208105,"accession_number":"0001628280-24-034277","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.","Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.","Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.","FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).","SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":228264000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225654,"accession_number":"0001628280-24-019999","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).","Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.","Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.","Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.","NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":146800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244815,"accession_number":"0001104659-24-011607","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Twist Bioscience stockholders elect Leproust and Chess as directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Emily M. Leproust re-elected with 33,957,330 votes for, 12,194,829 withheld; Robert Chess with 27,503,789 for, 18,648,370 withheld.","Advisory vote on NEO compensation approved: 43,215,571 for, 2,904,714 against, 31,874 abstentions.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 52,195,318 for, 61,548 against, 43,298 abstentions.","Approximately 90.51% of outstanding shares (52,300,164) were present in person or by proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244814,"accession_number":"0001628280-24-002998","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record Q1 revenue of $71.5M (+32% YoY); raises FY2024 guidance to $288M-$293M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.","Net loss of $43.0M ($0.75 per share) vs. $41.8M ($0.74 per share) in prior year.","Gross margin reached 40.5%, above previous guidance; FY2024 margin guidance raised to 40%-41%.","Appointed Adam Laponis as CFO; expanded Express Genes service to all prep scales.","Cash and investments of $311.1M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":71498000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244813,"accession_number":"0001104659-24-001628","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.","Annual base salary of $450,000; signing bonus $195,000 with clawback if terminated for cause within one year.","Target annual incentive for 2024 at 55% of base salary; equity grant includes 50,000 RSUs (4-yr vest, 1-yr cliff) plus 70,000 shares under exec comp programs.","Laponis previously CFO at Eargo, VP at Tesla, VP/CFO at Cardinal Health, and held roles at Johnson & Johnson.","No family relationships or related-party transactions with Laponis; disclosure via prior 8-K for Thorburn’s departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262255,"accession_number":"0001628280-23-039394","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports FY2023 revenue $245.1M (+20% YoY), net loss $3.60/sh; FY2024 guide $285-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $245.1M, up 20% from $203.6M; orders $264M, up 17% from $226.4M.","FY2023 net loss attributable to common stockholders $204.6M ($3.60 per share), down from $217.9M ($4.04) prior year.","Q4 revenue $66.9M, up 17% YoY from $57.3M; Q4 net loss $46.2M ($0.81 per share).","Guidance: FY2024 revenue expected $285M-$290M, reflecting growth.","Recent highlights: signed Bayer antibody deal worth up to $188M milestones; launched Twist Express Genes with 5-7 day turnaround."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":245109000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279453,"accession_number":"0001628280-23-027406","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Twist Bioscience reports Q3 FY2023 revenue of $63.7M (up 14% YoY); CFO to transition to new role","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $63.7M, up 14% YoY from $56.1M; net loss $57.4M ($1.01/share) vs $60.5M prior year.","CFO James Thorburn will transition to a new commercial/scaling role once successor is hired; search underway.","Cash and investments $357.1M at June 30, 2023; shipped products to ~2,200 customers.","Launched RNA sequencing portfolio; entered collaboration with Cancer Research Horizons."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":178163000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279452,"accession_number":"0001104659-23-087548","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K/A","filed_at":"2023-08-04T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Twist Bioscience reports $12.7M restructuring costs, exceeding prior $9-11M estimate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cumulative pre-tax restructuring costs of $12.7M recognized through June 30, 2023.","Broke down as $8.6M severance, $3.6M asset impairments, and $0.4M other costs.","Expects additional severance up to $0.4M and other costs up to $0.6M.","Restructuring includes ~270 employee reduction (25% of workforce) and facility consolidation.","Previous estimate of $9-11M was based on initial plan approved May 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297845,"accession_number":"0001104659-23-063421","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Twist Bioscience appoints Robert Werner as Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Werner appointed Chief Accounting Officer effective May 22, 2023; James Thorburn continues as CFO.","Werner receives $400K base salary, $100K bonus for FY2023, and 30,000 RSUs vesting over 4 years.","Werner previously served as CAO at Invitae (2020-2023) and as Corporate Controller at Proteus Digital Health.","Werner is a CPA with a Master's in Accountancy from Brigham Young University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297844,"accession_number":"0001628280-23-015988","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Twist Bioscience Q2 revenue record $60.2M (+25% YoY); cuts 270 jobs (~25% workforce)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $60.2M, up 25% YoY; orders $64.2M, up 17% YoY.","Net loss $59.2M ($1.04 EPS) vs $60.7M ($1.13) prior year.","Workforce reduction of ~270 employees (~25%); expects pre-tax charges $9-11M.","Withdrew prior FY2024 guidance; provided limited updated guidance focused on cost reduction.","Cash $387.7M; shipped to 2,100 customers, 152k genes."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":114423000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318095,"accession_number":"0001104659-23-037343","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Twist Bioscience CAO Kevin Yankton resigns; CFO Thorburn to serve as interim principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Yankton resigns as CAO effective May 19, 2023 to pursue other interests; no disagreement with company.","Company initiated search for replacement and engaged expert financial consultant reporting to CFO.","CFO James Thorburn will serve as principal accounting officer until a successor is appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318094,"accession_number":"0001104659-23-014513","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Twist Bio annual meeting elects directors, approves say-on-pay, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Keith Crandell and Jan Johannessen elected as Class II directors with 33.9M and 32.2M votes for, respectively.","Non-binding advisory vote to approve NEO compensation passed with 43.4M for, 3.7M against.","Ratification of Ernst & Young as independent auditor for FY2023 approved with 52.0M votes for, 17.6K against.","Approximately 91.92% of total outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318093,"accession_number":"0001628280-23-002145","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.","Net loss of $41.8M ($0.74/share) improved from $45.6M ($0.91/share) YoY.","Cash and investments $438.7M; first products shipped from Wilsonville Factory of the Future.","Customer count 2,060 (up from ~1,800); gene shipments ~134,000 (vs ~125,000).","Launched NGS panels for rare disease; Astellas collaboration; biopharma partners at 278 with 95 active programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":54243000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336376,"accession_number":"0001628280-22-030393","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.","Q4 FY2022 revenue $57.3M (up 51% YoY); net loss $51.1M ($0.91/share).","Full year orders $226M, up 42% YoY; shipped 558,000 genes vs 372,000 in FY2021.","FY2023 revenue guidance $261-269M; FY2024 target $350M.","Promoted Patrick Finn, Ph.D. to president and COO; partnered with Illumina and PacBio."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":203565000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336375,"accession_number":"0001104659-22-120392","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Twist Bioscience amends bylaws to add proxy access for 3% long-term stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proxy access provision allows stockholders/groups of up to 20 owning ≥3% for ≥3 years to nominate up to 2 or 20% of directors.","Deleted requirement for stockholder list examination at meetings to conform to recent Delaware law changes.","Added universal proxy rule requirements: nominating stockholders must confirm solicitation from ≥67% of voting power and provide evidence.","Other technical, conforming, and non-substantive changes included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336374,"accession_number":"0001104659-22-119241","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Twist Bioscience refutes Scorpion Capital short-seller report as misleading; Q4 results Nov 18","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Twist calls Scorpion Capital report 'highly misleading' with many distortions and inaccuracies.","Reaffirms commitment to truthful communication, ESG practices, and shipping from Factory of the Future in Jan 2023.","Will report fiscal Q4 and full-year 2022 results on Nov 18, 2022 before market open; conference call at 8am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336373,"accession_number":"0001104659-22-111354","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Twist Bioscience promotes Patrick Finn to President and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Finn, formerly Chief Commercial Officer, appointed President and COO effective October 25, 2022.","Finn joined Twist in 2015 and led sales growth from $2M (FY2016) to $184M (12 months ended June 30, 2022).","New role adds oversight of operations to commercial responsibilities.","Compensation: base salary $470,000, 60% bonus target, $100,000 one-time cash bonus, $10K/month housing allowance, and $4.4M in RSUs. equity award."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353775,"accession_number":"0001628280-22-021235","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).","Net loss $60.5M ($1.08/sh) vs $40.0M ($0.82/sh) in prior year.","Cash, cash equivalents and investments total $527.6M as of June 30, 2022.","FY2022 revenue guidance raised to $203M from prior outlook.","Launched Twist MRD Rapid 500 Panel, human monkeypox controls, and expanded EUA for SARS-CoV-2 NGS assay."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":146259000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371599,"accession_number":"0001104659-22-056448","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q2 revenue $48.1M (+54% YoY), orders $55.0M (+32% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $48.1M, up 54% YoY from $31.2M.","Net loss $60.7M ($1.13/share) vs $37.9M ($0.78) prior year.","Orders $55.0M, up 32% YoY from $41.7M.","Four-year supply agreement with Ginkgo Bioworks, $58M minimum purchases over contract term.","Cash $604.4M; raised $269.8M net from public offering completed in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":90145000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371598,"accession_number":"0001104659-22-048997","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Twist Bioscience COO Patrick Weiss steps down; internal promotions announced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Weiss resigns as COO effective April 21, 2022, for personal reasons; will stay as strategic advisor.","Tracey Mullen promoted to SVP of Operations; she joined via the Abveris acquisition in November 2021.","Nimisha Srivastava promoted to SVP of R&D; she has been with Twist since 2014, leading engineering.","Company initiates formal search for a new COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390555,"accession_number":"0001104659-22-032029","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Twist Bioscience dismisses PwC, appoints EY as independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PwC dismissed as auditor on March 3, 2022; its FY2020 and FY2021 audit reports were unqualified.","No disagreements with PwC on accounting principles or scope; material weaknesses in internal controls previously disclosed.","EY appointed as new auditor for FY2022 ending September 30, 2022, after audit committee selection process.","Previously reported material weaknesses include segregation of duties, revenue accuracy, and IT general controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390554,"accession_number":"0001104659-22-023542","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Twist Bioscience launches ~$287.5M common stock offering at $55.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5,227,272 shares (including full exercise of underwriter option) at $55.00 per share.","Underwriters led by J.P. Morgan, Goldman Sachs & Co. LLC, and Cowen and Company, LLC.","Closing expected on or about February 15, 2022, subject to customary conditions.","Offering via effective shelf registration statement on Form S-3 (No. 333-238906)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390553,"accession_number":"0001104659-22-015913","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Twist Bioscience shareholders elect four Class I directors at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nelson Chan re-elected with 20.5M for, 22.2M withheld; Xiaoying Mai with 33.5M for, 9.1M withheld.","Advisory vote on NEO compensation approved: 36.7M for, 5.9M against, 29k abstentions.","Ratification of PwC as auditor for FY2022: 46.9M for, 31.7k against, 36.9k abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390552,"accession_number":"0001104659-22-011724","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY2022: revenue $42M (+49% YoY), orders up 48%, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $42.0M (up 49% from $28.2M YoY); orders of $49.6M (up 48% from $33.6M).","Net loss $45.6M ($0.91 per share) vs $32.9M ($0.72 per share) in prior year.","Cash, cash equivalents and investments $408.7M as of Dec 31, 2021; shipped to ~1,800 customers.","Raised fiscal 2022 revenue guidance; specific numbers not provided in the press release excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":42018000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408594,"accession_number":"0001193125-21-346678","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2021-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Twist Bioscience completes acquisition of Abveris (AbX Biologics)","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Acquisition closed December 1, 2021, under merger agreement dated November 19, 2021.","Twist issued stock consideration; entered Registration Rights Agreement to register resale of those shares.","No financial terms (deal value, premium, or expected impact) disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408591,"accession_number":"0001104659-21-143057","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K/A","filed_at":"2021-11-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Twist Bioscience appoints Dr. Melissa Starovasnik to Compensation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Melissa Starovasnik was appointed to the Compensation Committee of the Board on November 17, 2021.","She was originally elected as a Class I director effective August 5, 2021, as previously reported.","The amendment solely adds this committee assignment; no other changes to prior disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408593,"accession_number":"0001104659-21-142602","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Twist Bioscience to acquire Abveris for up to $190M in stock and cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $190M: $150M at close (Twist stock + up to $10M cash) plus up to $40M stock tied to 2022 revenue target.","Stock price per share collared between $106.10 and $129.68 based on 30-day VWAP before closing.","Abveris adds in vivo antibody discovery platform (DiversimAb mice) to complement Twist's synthetic library and AI capabilities.","Acquisition expected to bolster Twist's biopharma antibody design, discovery, and screening services for partners and internal pipeline.","Deal structured as a merger; shares issued in private placement exempt from registration under Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408592,"accession_number":"0001104659-21-142578","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.","Q4 revenue $38.0M (+17% YoY); net loss $41.2M ($0.84/share) vs $24.3M ($0.54/share).","FY2022 revenue guidance $183M-$193M, representing ~42% growth at midpoint.","Cash and investments $477.9M at Sept 30, 2021.","Announced acquisition of Abveris to add in vivo antibody discovery capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":132333000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427524,"accession_number":"0001104659-21-102285","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Twist Bioscience appoints drug discovery leader Melissa Starovasnik to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Starovasnik appointed to board effective Aug 5, 2021; will receive $40k cash retainer (pro rata) and $340k in equity vesting over 3 years.","She spent nearly 30 years at Genentech, most recently as Senior Scientific Advisor, leading protein therapeutics discovery.","Kevin Yankton appointed principal accounting officer; previously Chief Accounting Officer at Varex Imaging; James Thorburn remains CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427523,"accession_number":"0001104659-21-101093","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2021-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).","Net loss $40.0M ($0.82/share) vs $28.2M ($0.67) YoY.","Gross margin 40%; cash $519.4M; raising FY2021 revenue guidance.","Shipped 107,000 genes (vs 83,000 YoY); acquired iGenomX for NGS tools.","Began shipping synthetic SARS-CoV-2 Delta RNA controls; appointed Dr. Melissa Starovasnik to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":94382000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}